<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cerebral <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arteriopathy</z:e> with subcortical <z:mpath ids='MPATH_124'>infarcts</z:mpath> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo> (CADASIL) is an inherited small vessel disease causing <z:hpo ids='HP_0001297'>stroke</z:hpo> and subcortical vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies in <z:hpo ids='HP_0003745'>sporadic</z:hpo> subcortical ischemic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular disease</z:e> have drawn attention to brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> as a clinically important marker of disease progression </plain></SENT>
<SENT sid="2" pm="."><plain>However, little is known about the role of brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> and its clinical correlates in CADASIL </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD: The authors determined the normalized brain volume (NBV) and percent brain volume change (PBVC) over 2 years in 76 CADASIL subjects (45.1 +/- 9.7 years) using the SIENA (structural image evaluation using normalization of <z:mpath ids='MPATH_127'>atrophy</z:mpath>) software and its adaptation for cross-sectional measurements (SIENAX) </plain></SENT>
<SENT sid="4" pm="."><plain>Baseline assessments included systolic blood pressure (SBP), <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels, BMI, and APOE genotyping </plain></SENT>
<SENT sid="5" pm="."><plain>T2-lesion volumes and clinical scales were assessed at both time points </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The NBV significantly correlated with <z:hpo ids='HP_0000001'>all</z:hpo> clinical scores (Rankin, NIH <z:hpo ids='HP_0001297'>Stroke</z:hpo> Scale, Barthel, structured interview for the diagnosis of Alzheimer <z:hpo ids='HP_0000726'>dementia</z:hpo> and multi-<z:mpath ids='MPATH_124'>infarct</z:mpath> <z:hpo ids='HP_0000726'>dementia</z:hpo>, Mattis <z:hpo ids='HP_0000726'>dementia</z:hpo> rating scale) at both time points independently of age and sex </plain></SENT>
<SENT sid="7" pm="."><plain>PBVC correlated with changes of <z:hpo ids='HP_0000001'>all</z:hpo> clinical scores (<z:hpo ids='HP_0000001'>all</z:hpo> p &lt; 0.01) except for the Mattis <z:hpo ids='HP_0000726'>dementia</z:hpo> rating scale (p = 0.10) </plain></SENT>
<SENT sid="8" pm="."><plain>In a linear regression model, age (p &lt; 0.001), male sex (p &lt; 0.01), and SBP (p = 0.07) were the main risk factors for a lower NBV at baseline </plain></SENT>
<SENT sid="9" pm="."><plain>Age (p &lt; 0.001) and SBP (p = 0.01) were risk factors for brain volume loss during follow-up </plain></SENT>
<SENT sid="10" pm="."><plain>Sample size estimates showed that the number of individuals needed to demonstrate a treatment effect in a trial can be reduced when PBVC is used as an endpoint </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This study identifies brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> as an important aspect of the disease process in CADASIL and establishes significant correlations with multiple clinical aspects including cognition </plain></SENT>
<SENT sid="12" pm="."><plain>Age and systolic blood pressure are risk factors for brain volume loss during follow-up </plain></SENT>
<SENT sid="13" pm="."><plain>Percent brain volume change seems promising as an adjunct outcome measure in future interventional trials </plain></SENT>
</text></document>